SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions
New funding will support ongoing clinical development of lead candidate, SBT101 for adrenomyeloneuropathy (AMN) Phase 1/2 study initiation of SBT101 expected in the second half of 2022 Pipeline development to continue, focused on spinal cord-related disorders PHILADELPHIA–(BUSINESS WIRE)–SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological … [Read more…]